To Evaluate the Efficacy and Safety of Initial Combination Therapy With DWP16001 and DWC202518 Compared to DWP16001 Monotherapy and DWC202518 Monotherapy in Patients With Type 2 Diabetes Mellitus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 510 participants.

Also called NCT07619833

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 510 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07619833
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07619833. Randomized; quadruple masking; primary purpose treatment. Start 2026-06 (anticipated); primary completion 2027-11 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
To Evaluate the Efficacy and Safety of Initial Combination Therapy With DWP16001 and DWC202518 Compared to DWP16001 Monotherapy and DWC202518 Monotherapy in Patients With Type 2 Diabetes Mellitus
Condition
T2DM (Type 2 Diabetes Mellitus)
Intervention (Drug)
DWP16001
Intervention (Drug)
DWC202518
Intervention (Drug)
Placebo of DWP16001
Intervention (Drug)
Placebo of DWC202518
Lead sponsor
Daewoong Pharmaceutical Co. LTD. (class: industry)

Record details

Record id
cardio:ct-nct07619833
Content hash
ded4977035eb4f904ba8865b24f12f34809bb2c06299af736303dd53e3468e7c